Cargando…
Proteasome Inhibitor YSY01A Abrogates Constitutive STAT3 Signaling via Down-regulation of Gp130 and JAK2 in Human A549 Lung Cancer Cells
Proteasome inhibition interfering with many cell signaling pathways has been extensively explored as a therapeutic strategy for cancers. Proteasome inhibitor YSY01A is a novel agent that has shown remarkable anti-tumor effects; however, its mechanisms of action are not fully understood. Here we repo...
Autores principales: | Huang, Wei, Yuan, Xia, Sun, Ting, Fan, Shujie, Wang, Jun, Zhou, Quan, Guo, Wei, Ran, Fuxiang, Ge, Zemei, Yang, Huayu, Li, Runtao, Cui, Jingrong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574410/ https://www.ncbi.nlm.nih.gov/pubmed/28883791 http://dx.doi.org/10.3389/fphar.2017.00476 |
Ejemplares similares
-
YSY01A, a Novel Proteasome Inhibitor, Induces Cell Cycle Arrest on G2 Phase in MCF-7 Cells via ERα and PI3K/Akt Pathways
por: Xue, Bingjie, et al.
Publicado: (2015) -
Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells
por: Huang, Wei, et al.
Publicado: (2016) -
Anticancer Effect of a Novel Proteasome Inhibitor, YSY01A, via G2/M Arrest in PC-3M Cells in vitro and in vivo
por: Zhang, Mei, et al.
Publicado: (2015) -
Narrative-based computational modelling of the Gp130/JAK/STAT signalling pathway
por: Guerriero, Maria Luisa, et al.
Publicado: (2009) -
Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting
por: Zanders, Lukas, et al.
Publicado: (2021)